What the Research Really Says About Omega-3 (EPA/DHA) — And What It Means for Formulators

Norway — 2 June 2026

Despite decades of market dominance and pervasive health messaging, are we truly understanding the evolving story of Omega-3s? With a global market that has grown steadily, the ingredient is a stalwart. Yet, beneath the surface of aggressive marketing and the 'more is better' concentration wars, significant questions persist regarding sourcing sustainability, clinical efficacy at commercial dosages, and the true cost-benefit for formulators. Is the industry chasing ever higher EPA/DHA percentages at the expense of genuine consumer benefit and environmental stewardship?

Latest developments — updated 11 September 2026

The Omega-3 landscape continues to evolve with significant shifts in supply, market dynamics, and formulation opportunities. New players are emerging in ingredient supply, with Louis Dreyfus Company acquiring BASF's health ingredients business, impacting plant sterols, CLA, and omega-3 availability, as reported via NutraIngredients Europe ("BASF Health Ingredients Sale Signals Ingredient Supply Shift"). Sustainability and novel sourcing remain key, with genetically modified camelina, rich in EPA/DHA, nearing commercialisation to address supply chain pressures, as highlighted via NutraIngredients Europe ("Omega-3 Crop Commercialisation Nears"). The lucrative Chinese market is a focus for innovation, seeing surging interest in omega-3s and novel ingredient approvals, with Zooca targeting this region with Calanus oil and new product formats like krill oil-infused adult milk powder, as reported via NutraIngredients Asia ("China Nutraceutical Market Sees Omega-3 and Novel Ingredient Growth"). Formulators are also adapting to new market demands, including targeted eye health formulations and opportunities arising from GLP-1 drug co-market strategies, as covered via NutraIngredients Europe ("GLP-1 Nutrition, Eye Health Formulations, and Japan FFC Market Evolve"). Meanwhile, regulatory bodies like ANSES are reinforcing the need for robust on-pack warnings and clearer dosing instructions for fortified products, including those in sports nutrition, as reported via NutraIngredients LATAM ("ANSES Warns on Sports Nutrition Over-Consumption"), underscoring the importance of responsible formulation and labelling.

What the Clinical Evidence Actually Shows

The clinical landscape for Omega-3s is both extensive and, at times, contradictory. Early observational studies and some randomised controlled trials (RCTs) suggested broad cardiovascular benefits, particularly in reducing triglyceride levels. For instance, studies utilising icosapent ethyl (a highly purified EPA ethyl ester) have demonstrated substantial reductions in major adverse cardiovascular events at high doses of 4g/day. However, it is crucial to note that these were pharmaceutical-grade interventions, not typical dietary supplements. Most over-the-counter supplements provide significantly lower doses, often in the range of 500-1000mg total EPA+DHA per serving. Meta-analyses of lower-dose supplementation have frequently shown only modest, if any, statistically significant reductions in primary cardiovascular endpoints for the general population. The leap from pharmaceutical-grade, high-dose EPA in specific patient cohorts to general population health claims for standard supplements is a chasm often ignored by marketers. Furthermore, many studies are funded by industry, raising questions about potential publication bias or selective reporting of favourable outcomes. The evidence for cognitive function and eye health, while promising in some early-stage research, often lacks the robust, large-scale RCTs needed for definitive conclusions.

The Formulation Reality

Formulating with Omega-3s presents a unique set of challenges, predominantly centred on bioavailability, oxidative stability, and sensory attributes. The two primary forms available are triglycerides (TG) and ethyl esters (EE). While EE forms allow for higher concentrations of EPA/DHA, TG forms are generally considered to have superior bioavailability, a factor often overlooked in the race for headline potency. Excipient selection is critical; antioxidants such as tocopherols or rosemary extract are essential to mitigate lipid peroxidation, which can degrade the active compounds and lead to rancidity – a significant consumer complaint. Microencapsulation technologies are advancing, offering improved stability and masking of fishy odours, but these add considerable cost and complexity. Lead times for high-concentration, stable Omega-3 concentrates can be substantial, particularly for novel algal sources, impacting inventory management and speed to market. In our experience as a manufacturer, formulators must balance the desire for high potency with the practicalities of absorption, stability, and consumer palatability.

Market Position and Commercial Viability

The Omega-3 market is mature but continues to see innovation, especially in alternative sourcing and ultra-high concentrations. The market has grown steadily, driven by an ageing population and increasing health consciousness. However, this growth disguises intense pricing pressures. The 'concentration wars' have led to a commoditisation of standard fish oil, squeezing margins for manufacturers who cannot differentiate. Minimum order quantities (MOQs) for highly concentrated or novel forms, such as algal DHA, can be substantial, posing a barrier for smaller brands. Achieving a healthy margin in this segment requires either significant volume, a highly differentiated product (e.g., specific delivery format, unique blend), or a strong brand narrative around sustainability and provenance. The days of simply launching another 1000mg fish oil capsule are over. Brands must offer genuine added value, whether through superior bioavailability, verified sustainability, or targeted formulations, to command a premium.

What This Means for Norway

Norway holds a formidable position in the global Omega-3 supply chain, particularly for marine-sourced EPA/DHA, due to its robust fishing industry and advanced processing capabilities. Regulatory oversight, primarily through the Norwegian Food Safety Authority (Mattilsynet), ensures high standards for purity and heavy metal content, which is a significant competitive advantage. Consumer demand within Norway, much like the broader European market, is increasingly leaning towards sustainability and transparency. Brands leveraging Norwegian provenance can command a premium, provided they can substantiate their claims of sustainable fishing practices (e.g., MSC certification). However, the rise of algal-sourced Omega-3s presents a long-term challenge to the traditional marine oil dominance, necessitating innovation in Norwegian processing and potential diversification into aquaculture-derived alternatives.

The Bottom Line for Formulators

Formulators should approach Omega-3 investment with strategic caution. While the market remains substantial, success hinges on differentiation. Prioritise bioavailable forms (TG over EE where possible), invest in robust stability testing, and critically evaluate the true clinical benefit of claimed dosages. Consider algal sources for their sustainability credentials and appeal to vegetarian/vegan consumers, despite potentially higher costs and MOQs. Do not blindly chase concentration numbers; instead, focus on delivering a stable, absorbed, and genuinely effective product that can justify its price point through clear consumer benefits and transparent sourcing. Only then will Omega-3s truly deliver on their promise.